Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression

Abstract

Objectives: This study was aimed to investigate the efficacy and safety of vortioxetine hydrobromide in the treatment of major depressive disorder (MDD).
 Methods: One hundred and eighty patients with the newly diagnosed depression in our hospital between August 2018 and August 2019 were selected and randomly divided into an observation group and a control group, 90 each group. The control group was treated with escitalopram, and the observation group was treated with voltaxetine. The efficacy and adverse reactions were evaluated by the Hamilton Depression scale-17 (HAMD-17), Sheehan Disability Scale (SDS), Perceived Deficits Questionnaire-Depression (PDQ-D), and treatment emergent symptom scale (TESS) before treatment and at the end of the 8th and 24th week after treatment.
 Results: At the end of the 8th and 24th week after treatment, the HAMD-17 scores of the two groups were lower than those before treatment (P<0.05); at the end of the 8th and 24th week after treatment, the PDQ-D and SDS scores of the two groups were lower than those before treatment (P<0.05), and the above scores of the observation group were lower than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).
 Conclusion: Voltaxetine can improve cognitive function and clinical symptoms of patients with severe depression and has high safety, which is worth clinical attention.
 doi: https://doi.org/10.12669/pjms.38.5.5230
 How to cite this:Shao S, Sun B, Sun H. Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression. Pak J Med Sci. 2022;38(5):---------. doi: https://doi.org/10.12669/pjms.38.5.5230
 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea

“…Similarly, patients reported significant improvements in cognitive function via both DSST and PDQ-K. These results echoed the significant improvements in clinical symptoms and patient reported cognitive function reported in RCTs and/or real-world studies of vortioxetine (19,25,26,33,35,36).…”

The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature

“…Some of these studies (n = 5) found vortioxetine to be superior in mood symptom reduction than the active comparator, including agomelatine [43,44], venlafaxine [45], desvenlafaxine [46] and duloxetine [47]. Other experiences (n = 4) found vortioxetine to be more effective in cognitive symptom reduction with respect to escitalopram, paroxetine, and duloxetine [48][49][50][51]. Half of these trials (n = 11) found no significant difference between vortioxetine compared to sertraline [52], venlafaxine [53,54], desvenlafaxine [55,56], escitalopram [55][56][57][58], vilazodone [57], and duloxetine [59][60][61][62], although duloxetine tended to perform better in these studies.…”